MedTrace Logo

Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological

NCT06968299 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-24

No results posted yet for this study

Summary

This open-label, single-group, pre/post-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability. It is expected that 40 subjects aged 18 years and above will be recruited, with a target of 30 cases, to take ExoBDNF probiotics for a total of 8 weeks.

Conditions

  • Cognitive Functions Perceptual Disturbances
  • Cognitive Function Abnormal
  • Sleep
  • Psychological

Interventions

DIETARY_SUPPLEMENT

ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules

Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.

Sponsors & Collaborators

  • SunWay Biotech Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Hsin-An Chang, MD · Director, Child and Adolescent Psychiatry, Department of Psychiatry

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06968299 on ClinicalTrials.gov